In 2008, Harbin Pharmaceutical Group embarked on a unique development track, which can be described as "reflecting different colors of lotus flowers", presenting a beautiful performance table to the industry, shareholders, society and employees: the sales revenue of the whole group reached 654.38+0.274 billion yuan, with a compound average growth rate of 654.38+05.2% and 654.2% in 654.38+00. According to incomplete statistics, in 2009, the industrial added value of group companies increased by12.16% year-on-year; Operating income increased17.95438+0% year-on-year; The profit increased by 65,438+05.05% year-on-year, of which the growth rate of operating income was 6 percentage points higher than the average growth rate of the top 25 pharmaceutical listed companies in China, and the profit growth rate was 4 percentage points ahead. Since the establishment of 1989 Harbin Pharmaceutical Group, the comprehensive economic benefits of Harbin Pharmaceutical Group have ranked first among pharmaceutical enterprises in Heilongjiang Province for 20 consecutive years. Since 2005, the profit index and brand value have ranked first among 4738 pharmaceutical enterprises in China for five consecutive years. In 2009, the brand evaluation value of Harbin Pharmaceutical reached as high as151900,000 yuan, an increase of 670 million yuan year-on-year, ranking among the top 500 brands in Asia. The group's economic aggregate, operating quality and competitiveness have been steadily improved, and its development vitality has been significantly enhanced. With the advantages of independent innovation, Harbin Pharmaceutical Group is getting closer and closer to the grand strategic goal of "innovative world-class new Harbin Pharmaceutical".